Search

Your search keyword '"Slager, S."' showing total 363 results

Search Constraints

Start Over You searched for: Author "Slager, S." Remove constraint Author: "Slager, S."
363 results on '"Slager, S."'

Search Results

6. P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER

7. P656: INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY

10. Exploring provider perspectives on patients with atrial fibrillation who are not prescribed anticoagulation therapy

13. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL

15. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk

16. Two truncating variants in FANCC and breast cancer risk.

17. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.

18. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

19. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

20. Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer

21. Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk.

27. Two truncating variants in FANCC and breast cancer risk

28. Cancer Causes Control

29. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes.

30. Two truncating variants in FANCC and breast cancer risk

31. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

32. Polygenic risk scores for prediction of breast cancer and breast cancer subtypes

33. What are they trying to do?: An analysis of Action Identities in using electronic documentation in an EHR

34. Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation (vol 5, 4999, 2014)

35. Aandacht voor arbo gaat niet vanzelf: organisatietypen en preventiebeleid

36. PRE-TREATMENT HEMOGLOBIN AND OUTCOME IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ANTHRACYCLINE CONTAINING CHEMOTHERAPY

37. PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

38. Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

39. Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in BRCA1 and BRCA2 mutation carriers

40. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

41. Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade

42. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukemia

44. Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation

45. Evidence that the 5p12 variant rs10941679 confers susceptibility to estrogen receptor positive breast cancer through FGF10 and MRPS30 regulation

46. Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk

47. BRCA2 polymorphic stop codon K3326X and the risk of breast, prostate, and ovarian cancers

48. PALB2, CHEK2 and ATM rare variants and cancer risk:data from COGS

49. Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma

50. CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS

Catalog

Books, media, physical & digital resources